Tempest Therapeutics

Developing targeted, immune-mediated oral cancer therapies for broad patient benefit

placeSan Francisco, California, United States calendar_todayFounded 2011 groups19 employees language tempesttx.com

Registered entities

Investor mix

9 investors on record; lead investors include F-Prime Capital, Versant Ventures, Quan Capital; 2 have since exited.

Investor typeCountShare
Venture capital778%
Private equity111%
Other / undisclosed111%
Coming soon